A Nanostructured Drug Delivery Approach For Improved Colorectal Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$560,072.00
Summary
Based on nanotechnology a new medicine will be developed for chemotherapy drugs. Drugs that are currently only delivered by injection will be able to be taken as an orally dosed tablet. A novel therapy for colorectal cancer will be advanced with potential improved clinical outcomes and reduced side-effects, e.g. nausea and diarrhoea. Cancer patients will no longer need to visit the hospital for injection therapy and therefore reducing the burden on the health service.
Polymyxin-like Lipopeptide Antibiotics Of The Future
Funder
National Health and Medical Research Council
Funding Amount
$335,323.00
Summary
Polymyxins are now being clinically used as the ‘last-line’ therapy for infections caused by multidrug-resistant Gram-negative ‘superbugs’. For the first time our novel approach will interface chemistry and biology of the polymyxins with the purpose of creating a new generation of safer and more efficacious polymyxin antibiotics.
Regulation Of Drug Detoxifying UDP Glucuronosyltransferases
Funder
National Health and Medical Research Council
Funding Amount
$590,945.00
Summary
Some organs in the body are particularly sensitive to fat-soluble chemicals taken in from the environment or present in food. They are also sensitive to hormones and other small molecule products of metabolism. Controlling the levels of these potentially toxic chemicals is essential in order to maintain the health of the organ. In this work we will investigate the regulation of detoxifying enzymes that protect these organs by inactivating and hastening the elimination of fat-soluble chemicals.
Specific Targeting Of Nanosystems By Cutaneous Delivery
Funder
National Health and Medical Research Council
Funding Amount
$985,026.00
Summary
Substances have long been applied to the skin for therapeutic or cosmetic purposes, but the range of suitable compounds is limited. Consequently, there is a need for a wider range of compounds which can be delivered effectively into the skin for targeted treatment, diagnostic imaging and vaccination. New nanomaterial drug delivery systems are being increasingly used for these purposes. We seek to understand the properties of nanosystems that will enable improved drug targeting via the skin.
Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$653,137.00
Summary
Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
Prevention Of Heart Damage During Anthracycline Cancer Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$327,214.00
Summary
Doxorubicin is an effective medicine widely used for the treatment of cancer. However, it can cause heart damage, which not only creates a new health problem, but also limits the length of doxorubicin treatment cancer patients can receive, and therefore the likelihood of cancer cure. Preventing heart damage by doxorubicin is therefore important to improve overall cancer cure rates and patient health. This study aims to develop new medications to prevent heart damage during cancer chemotherapy.
Advanced Imaging To Define Hepatic & Intestinal Drug Disposition In Aging & Liver Diseases
Funder
National Health and Medical Research Council
Funding Amount
$762,123.00
Summary
Aged people and liver disease patients have impaired drug absorption and elimination functions. Their response to drugs varies widely when given drug dosage regimens recommended for normal patients. This project will explore the possibility of using in vivo imaging techniques to define the gut and liver function and their response to administered drugs. This grant will help the selection of appropriate drugs and doses for aged people and patients with liver diseases, i.e. personalised medicine.
SULT4A1 is not a sulfotransferase, but a sulfotransferase inhibitor. It forms high affinity heterodimers with other sulfotransferases via a conserved dimerisation site in its carboxyl terminus attenuating catalytic activity. Consequently, it is important for the metabolism of numerous important molecules including estrogens, thyroid hormones, neurotransmitters and many therapeutic agents.
Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Transient Receptor Potential Channels, Calcium And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$410,284.00
Summary
This research outlined in this application aims to uncover the molecular mechanisms that cause Alzheimer's disease (AD). Specifically the research will examine the mechanism by which Abeta, a protein which plays a central role in AD, causes neurodegeneration. The significance of this work is that it may help to identify new targets for AD drug development.